COVID-19 Drug Treatment study on BDC (899 participants)

phs003708 — CONNECTS Master Protocol for Clinical Trials targeting Macro- and    Micro-Immuno-Thrombosis, Vascular Hyperinflammation, and    Hypercoagulability and Renin-Angiotensin-Aldosterone System (RAAS) in    Hospitalized Patients with COVID-19 (ACTIV-4 Host Tissue)

ACTIV 4 Host Tissue is a shared-placebo clinical trial platform evaluating therapies targeting the host response to COVID-19 in hospitalized patients. The overarching goal of the platform was to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19. Three trials were implemented to investigate three agents: TXA-127, TRV-027, and Fostamatinib. These agents all impact the host tissue response in COVID-19 via a number of unique mechanisms, including potential beneficial effects on the RAAS system and formation of neutrophil extracellular traps (NETs). Each trial evaluated the efficacy of these agents' ability to impact the host tissue response and improve outcomes in patients hospitalized with COVID-19. We found no evidence that any of the three agents significantly improved clinical outcomes as measured by the primary outcome, oxygen free days through day 28.

CONNECTS Master Protocol for Clinical Trials targeting Macro- and    Micro-Immuno-Thrombosis, Vascular Hyperinflammation, and    Hypercoagulability and Renin-Angiotensin-Aldosterone System (RAAS) in    Hospitalized Patients with COVID-19 (ACTIV-4 Host Tissue)